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Abstract
Otosclerosis is a relatively common heterogenous condition, characterized by abnormal bone remodelling in the otic capsule
leading to fixation of the stapedial footplate and an associated conductive hearing loss. Although familial linkage and
candidate gene association studies have been performed in recent years, little progress has been made in identifying disease-
causing genes. Here, we used whole-exome sequencing in four families exhibiting dominantly inherited otosclerosis to
identify 23 candidate variants (reduced to 9 after segregation analysis) for further investigation in a secondary cohort of 84
familial cases. Multiple mutations were found in the SERPINF1 (Serpin Peptidase Inhibitor, Clade F) gene which encodes PEDF
(pigment epithelium-derived factor), a potent inhibitor of angiogenesis and known regulator of bone density. Six rare
heterozygous SERPINF1 variants were found in seven patients in our familial otosclerosis cohort; three are missense
mutations predicted to be deleterious to protein function. The other three variants are all located in the 50-untranslated
region (UTR) of an alternative spliced transcript SERPINF1-012. RNA-seq analysis demonstrated that this is the major
SERPINF1 transcript in human stapes bone. Analysis of stapes from two patients with the 50-UTR mutations showed that they
had reduced expression of SERPINF1-012. All three 50-UTR mutations are predicted to occur within transcription factor
binding sites and reporter gene assays confirmed that they affect gene expression levels. Furthermore, RT-qPCR analysis of
stapes bone cDNA showed that SERPINF1-012 expression is reduced in otosclerosis patients with and without SERPINF1
mutations, suggesting that it may be a common pathogenic pathway in the disease.
Introduction
Otosclerosis is one of the most common causes of hearing im-
pairment among young adults. It is characterized by abnormal
bone homeostasis within the otic capsule (1). The remodelling
process often involves the stapedio-vestibular joint, and can
lead to fixation of the stapedial footplate and a conductive
hearing loss that result in clinical otosclerosis. Histological oto-
sclerosis is seen more frequently than clinical otosclerosis;
however in these cases, the stapes is not fixed and the diagnosis
can only be made post-mortem (2). The age of onset is variable,
although hearing loss in clinical otosclerosis typically begins in
the third decade and progressively becomes more severe.
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Hearing loss is bilateral in 70–85% of cases and is usually asym-
metrical, developing initially in one ear before progressing to the
other (3). Patients choose to undergo surgery to replace all or part
of the affected stapes with a prosthetic device which ameliorates
the hearing loss to varying degrees. Alternatively, the condition
can be managed with hearing-aids (4).
The clinically relevant form of otosclerosis is relatively com-
mon in individuals of Indian and European extraction with a re-
ported frequency of 0.3–0.4% in white Europeans; it is much
rarer in African, Native American and other Asian populations
(4–7). In most individuals, otosclerosis appears to be sporadic
and is considered a complex condition with both environmental
and genetic factors contributing (7–9). However, otosclerosis
also occurs with a strong familial inheritance pattern in up to
50% of cases. The pattern of inheritance in familial otosclerosis
is most often consistent with an autosomal dominant mutation
that exhibits variable penetrance estimated at 80–90% (7).
To date, otosclerosis has proved resistant to analysis by con-
ventional genetic techniques. Variable penetrance limits the
power of linkage analysis, and so although eight genetic loci have
been linked to otosclerosis these chromosomal regions are very
large and contain many genes (10–17). As a result, no causal muta-
tions underlying familial otosclerosis have yet been identified lim-
iting progress in therapeutic development (7–9). With the recent
advances in sequencing technologies, there have been numerous
reports of novel genetic mutations identified using whole-exome
sequencing (WES), including the identification of genes involved
in rare Mendelian disorders that had previously eluded re-
searchers (18). Furthermore, although more challenging, there is
great interest in extending these technologies to common, com-
plex traits (19). Otosclerosis is a heterogeneous disorder in the
population but one that often occurs in multiple members of the
same family consistent with a monogenic type of inheritance.
Hence, a WES approach in these families may provide a powerful
discovery tool to reveal the genetic causes and molecular path-
ways disrupted in otosclerosis. However, because of the frequency
of the disease the causal variants are unlikely to be identified by
WES alone as frequency filters will have to be set higher than in
rare disorders. In this work, we used a combination of WES, RNA-
seq and functional analysis to identify disease-causing genes in
familial otosclerosis (Fig. 1A). In one family, we detected a rare
heterozygous missense variant, c.601G>A, in SERPINF1 (Serpin
Peptidase Inhibitor, Clade F; Fig. 1B). Five additional rare variants
were identified in SERPINF1 from a cohort of 84 familial cases of
otosclerosis. We analysed the effect of these mutations and iden-
tified SERPINF1 as the first disease-causing gene in otosclerosis.
Results
WES in four families identifies candidate variants for
otosclerosis
We sequenced the exomes of 10 individuals from four families with
familial otosclerosis, three of European ancestry and one of mixed
European and Caribbean ancestry in which the otosclerosis has been
inherited via the European ancestral line. Exome capture was per-
formed with an Agilent SureSelect Human All Exon 50 Mb Kit and
subject to massively parallel sequencing. An average of 16.5 Gb of se-
quence was generated per individual as paired-end 100 bp reads.
Reads were mapped to the reference sequence (GRCh37_hs37d5)
with 96.16% of the bases mapping at >10 coverage. The mean
depth of coverage was 178.5-fold with an average of 89 656 variants
Figure 1. Familial otosclerosis and the next-generation sequencing approach for discovering causal variants. (A) Schematic presenting the workflow implementing a
combination of whole-exome sequencing, RNA-seq and functional analysis to identify disease-causing variants in familial otosclerosis. (B) Pedigree of Family B shows
an autosomal dominant inheritance pattern, consistent with familial otosclerosis. A rare heterozygous missense variant, c.601G>A, was identified in SERPINF1. Open
symbol, clinically unaffected; black symbol, confirmed otosclerosis; light grey symbol, other hearing loss; arrow, proband.
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identified per individual. A filtering strategy was applied to the data
in order to prioritize the identified variants (Table 1).
Firstly, variants were filtered within families so that only vari-
ants common to all affected individuals were retained. We focused
on non-synonymous variants, those affecting splice sites and inser-
tions–deletions (indels) in coding genes. Variants in non-coding
genes (with the exception of micro RNAs) and changes within non-
coding regions of genes that were not predicted to affect splicing
were filtered out. Known variants with a frequency >0.02 were fil-
tered out based on the September 2011 release of 1000 Genomes
Project and 500 Exomes Project. This was based on a reported oto-
sclerosis frequency of 0.003–0.004 in Europeans (4,6), of which up to
50% are familial with a dominant inheritance meaning that a famil-
ial otosclerosis causal variant would have a frequency of 0.0015–
0.002 if homogenous. A filter set 10-fold higher than this is assumed
to retain the causal variant especially as there is good evidence that
familial otosclerosis is heterogeneous. At this stage, two parallel fil-
tering pipelines were applied (Table 1). These were (i) a robust ‘na-
ive pipeline’ based on retaining variants predicted to be deleterious
by either PolyPhen-2 (20) or SIFT (21) and absent from dbSNP134;
and (ii) a ‘candidate-gene pipeline’ where only variants in an oto-
sclerosis candidate gene list of 494 genes were retained. The list in-
cluded genes implicated in otosclerosis from association studies
(22–26), gene expression studies (27), genes within linked regions of
the genome (10–17,28) and genes known to be involved in other
connective tissue disorders that can exhibit an otosclerosis-like
hearing loss (29–33). The list also included 176 genes found to be
differentially expressed in otosclerotic stapes by an RNA-seq analy-
sis of 12 stapes (J.L. Ziff, J.A. Lavy, S.R. Saeed and S.J. Dawson, manu-
script in preparation). Finally, for both pipelines variants were
removed if they were also present in a previous in-house exome se-
quencing project of 20 individuals without otosclerosis.
The remaining variants from both pipelines were annotated and
23 prioritized for follow-up firstly in segregation analysis
(Supplementary Material, Table S3). Prioritization was based on a
number of factors including GERP score, predicted effect of the vari-
ant, expression in otosclerotic and control stapes and known biologi-
cal role. Fourteen of 23 variants were ruled out due to lack of familial
segregation leaving nine candidate variants in the following genes:
ANKS1A (c.1291C>A), SERPINF1 (c.601G>A), VPS53 (c.107C>G),
TRIM17 (c.915C>G), COL1A2 (c.808G>A), FZD2 (c.655C>T), GNGT1
(c.82C>A), mir183 (n.81G>T) and ZNF225 (c.1698A>T).
Additional SERPINF1 variants identified in a familial
otosclerosis cohort
The remaining nine segregated variants were genotyped in 53
further unrelated individuals with a family history of
Table 1. Variant filtering process applied to whole-exome sequencing data in four families with otosclerosis
Filters Number of retained variants following application of filter
Family A Family B Family C Family D Average
All variants 88 295 93 972 88 373 87 983 89 656
Quality score > 30 82 689 87 135 82 983 83 058 83 966
Present in all affected individuals
in family
58 538 65 275 58 775 55 454 59 511
Exclude variants >0.02 freq
1000G
5924 8339 5844 5865 6493
Exclude variants in 500 Exome
Projecta
4001 — 3910 3925 5044
Exclude synonymous variants 729 1540 695 757 930
Exclude variants in non-coding
genes
278 873 279 285 429
Exclude variants in unaffected
individualsb
— 314 — — 289
Candidate filters Cand Naive Cand Naive Cand Naive Cand Naive Naive filters
Present in candidate gene list 26 112 26 158 27 94 29 112 Retain deleterious
changes
33 50 31 37 Retain if absent from
dbSNP
Exclude homozygous allelesc 18 28 — — 17 29 — — Exclude homozygous
alleles c
Exclude if on in-house WES
database
8 22 12 44 3 21 8 27 Exclude if on in-
house WES
database
Combined 30 56 23 35
Prioritized for follow up 4 8 4 7
Two affected individuals were subject to exome sequencing in families A, B and C and three in Family D. One unaffected individual was also subject to exome sequenc-
ing in Family B. After initial filtering (upper panel), variants were filtered in two parallel strategies (lower panel); a candidate gene filter and a robust naive filter based
on predicting deleterious variants and rarity. The retained variants were then combined and prioritized for follow up.
aNot applied to Family B as the ethnicity of this cohort was not applicable.
bOnly applied to Family B as only family with unaffected individual.
cNot applied to Family B or Family D as both originated from relatively small communities, highlighting a small possibility of the condition exhibiting an autosomal re-
cessive inheritance pattern.
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otosclerosis by Sanger sequencing of the exon and exon/in-
tron boundaries. None of the variants listed above was de-
tected in the cohort of 53 unrelated cases of familial
otosclerosis. However, a second rare non-synonymous vari-
ant (c.441G>C) was found in the SERPINF1 gene in two unre-
lated individuals. Exon 5 of SERPINF1 was subsequently
sequenced in a further 31 unrelated individuals with a family
history of otosclerosis identifying a novel 3 bp deletion (c.440-
40_440-38delTCG) in one individual. None of these variants
was found in 175 control samples sequenced. Further se-
quencing of all coding exons and intron–exon junctions in
SERPINF1 in the otosclerosis cohort revealed three additional
rare non-synonymous mutations in exon 3 and exon 4 of
SERPINF1 (c.167C>G, c.331G>A, c.392C>A). In summary, six
rare heterozygous variants were identified in seven unrelated
patients in the SERPINF1 gene (see Table 2). Allele frequencies
of the SERPINF1 variants identified were much greater in the
unrelated otosclerosis cohort compared with their reported
frequencies in the variant databases, 1000 Genomes and
NHLBI Exome Sequencing Project.
The c.167C>G, c.331G>A and c.392C>A missense variants
cause p.Ala56Gly, p.Asp111Asn and p.Ala131Asp changes, re-
spectively, and are all predicted to be damaging by both
PolyPhen-2 (20) and MutationTaster (34) (Table 3). The remain-
ing variants c.441G>C, c.601G>A and c.440-40_440-38delTCG
are predicted to have benign effects on the SERPINF1-001 tran-
script (ENST00000254722). However, all three variants are lo-
cated within the 50-untranslated region (UTR) of the shorter
alternatively spliced SERPINF1-012 transcript (ENST00000573
763) which contains exons 5–8 only (see Fig. 2A).
SERPINF1 transcript expression in control and
otosclerotic stapes
To determine whether the mutations in SERPINF1-012 50-UTR
may play a role in otosclerosis, we examined the read counts
for each SERPINF1 exon in the RNA-seq data from stapes bone to
assess alternatively spliced isoform expression (Fig. 2B). In con-
trol stapes (n¼ 4), it was found that the average read counts in
SERPINF1 exons were greater for exons 5–8 than exons 1–4. This
Table 2. Rare variants in SERPINF1 identified in a cohort of unrelated individuals with familial otosclerosis
Transcript SERPINF1-001 Transcript SERPINF1-012
Sample ID Identifier Otosc (n) Controls 1000G NHLBI Nucleotide
exchangea
Exon Protein
effect
Nucleotide
exchangeb
Exon Protein
effect
OTSC147 rs76119062 0.9% (1)c – n.d. 0.01% c.167C>G 3 p.Ala56Gly – – –
OTSC140 None 0.9% (1)c – n.d. n.d. c.331G>A 4 p.Asp111Asn – – –
OTSC383 rs148005190 0.9% (1)c – n.d. 0.08% c.392C>A 4 p.Ala131Asp – – –
OTSC319 None 0.6% (1)d n.d. n.d. n.d. c.440-40_440-
38delTCG
– – c.-202_-200
delTCG
1 50-UTR
OTSC354;
OTSC161
rs138341386 1.1% (2)d n.d. n.d. 0.03% c.441G>C 5 p.Lys147Asn c.-161G>C 1 50-UTR
OTSC134 rs137997656 0.6% (1)d n.d. n.d. n.d.e c.601G>A 5 p.Asp201Asn c.-1G>A 1 50-UTR
Allele frequencies of the variants are shown in the unrelated otosclerosis cohort, Otosc; a control cohort (n¼175), Controls; the 1000 Genomes Project (Phase 3
European, n¼503), 1000G; and the NHLBI Exome Sequencing Project (ESP6500 European-Americans, n¼4300), NHLBI. Effects on the amino acid structure of SERPINF1-
001 and SERPINF1-012 are shown. n.d., not detected.
aGenBank: NG_028180.1; Ensembl Transcript: ENST00000254722.
bEnsembl Transcript: ENST00000573763.
cn¼57.
dn¼88.
eThe individual with c.601G>A is of mixed European and Caribbean origin; the frequency of c.601G>A in NHLBI ESP6500 cohort Americans of African extraction is
0.3% (n¼2203).
Table 3. Summary of in silico and functional analysis of identified SEPRINF1 variants
Transcript SERPINF1-001 Transcript SERPINF1-012
Nucleotide
exchangea
Exon Protein
effect
PolyPhen-2
(HumDiv Score)
MutationTaster
(probability)
Nucleotide
exchangeb
Exon Protein
effect
Mfold TF binding Luciferase
activity
c.167C>G 3 p.Ala56Gly Probably damaging
(0.988)
Disease causing
(0.999)
— — — — — —
c.331G>A 4 p.Asp111Asn Possibly damaging
(0.879)
Disease causing
(0.999)
— — — — — —
c.392C>A 4 p.Ala131Asp Probably damaging
(0.969)
Disease causing
(0.707)
— — — — — —
c.440-40_440-
38delTCG
— — — Polymorphism
(0.999)
c.-202_-200
delTCG
1 50-UTR Affected Affected Affected
c.441G>C 5 p.Lys147Asn Benign (0.135) Disease causing
(0.995)
c.-161G>C 1 50-UTR No change No change Affected
c.601G>A 5 p.Asp201Asn Benign (0.000) Polymorphism
(0.999)
c.-1G>A 1 50-UTR No change Affected Affected
aGenBank: NG_028180.1; Ensembl Transcript: ENST00000254722.
bEnsembl Transcript: ENST00000573763.
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suggests that the SERPINF1-012 transcript, which contains exons
5–8 only, is the major SERPINF1 isoform in the stapes.
Additionally, analysis of stapes tissue from the proband in
Family B with the c.601G>A variant in the 50-UTR of SERPINF1-
012 indicated that levels of this transcript are reduced in this in-
dividual suggesting that they do affect expression. Moreover,
the average read counts for SERPINF1 exons 5–8 were signifi-
cantly reduced in otosclerotic stapes (n¼ 8) compared with con-
trol stapes (P< 0.05; Fig. 2B), whereas no significant differences
were observed for the average read counts in exons 1–4 between
control and otosclerotic stapes.
Expression of SERPINF1 transcripts was further investigated
in a second, larger sample of stapes using RT-qPCR. This con-
stituted stapes suprastructure from 75 unrelated affected indi-
viduals, 5 control individuals and 1 affected individual with
the c.441G>C mutation in the 50-UTR of SERPINF1-012. RT-
qPCR was used to determine the relative expression of up-
stream (assay spanning exons 3 and 4) and downstream exons
(assay spanning exons 6 and 7), which relate to SERPINF1-001
and SERPINF1-012 transcripts, respectively (see schematic in
Fig. 2A). A large 2.4-fold reduction was found for the down-
stream assay in the stapes from the individual with the
c.441G>C mutation compared with controls suggesting that
this SERPINF1-012 transcript is affected by the variant in the 50-
UTR of this transcript (P< 0.0005; Fig. 2D). In addition, we
found that the level of SERPINF1 mRNA is significantly reduced
in the general otosclerosis sample for both assays compared
with controls (Fig. 2C and D). This reduction is greater for the
downstream exons (1.9-fold, P< 0.00005) contained within
SERPINF1-012 than for upstream exons (1.3-fold, P< 0.05), con-
sistent with RNA-seq data.
Investigating the effect of SERPINF1-012 50-UTR variants
on expression
Annotation of non-coding variants and prediction of their effects
are still limited, meaning that the evaluation of effect of the 50-UTR
variants on SERPINF1 requires further investigation. Data from RT-
qPCR and RNA-seq indicated that two of the mutations in the 50-
UTR reduce SERPINF1-012 expression in stapes removed from these
individuals. 50-UTR variants can affect regulation of both transcrip-
tion and translation, either by affecting the binding of transcription
factors or by altering the stability of the mRNA through changes in
secondary structure. In silico analysis using a transcription factor
prediction tool, MatInspector (35), predicted that the three
SERPINF1-012 50-UTR variants are within various transcription fac-
tor binding sites (see Supplementary Material, Table S4). Most no-
tably, both the c.440-40_440-38delTCG and c.601G>A variants
were predicted to create binding sites for transcription factors in-
volved in bone regulation; PAX3 (c.440-40_440-38delTCG), RBPJ and
NFYA (c.601G>A) (36–38). We also investigated the effects of the
50-UTR variants on RNA folding using Mfold (39), which predicts
RNA structure based on free energy minimization. RNA structures
of the 50-UTR alone and the full length SERPINF1-012 mRNA were
predicted (Supplementary Material, Fig. S1). The c.440-40_440-
Figure 2. SERPINF1 transcript expression in control and otosclerotic stapes. (A) SERPINF1-001 and SERPINF1-012 transcripts (not to scale) with the identified variants in-
dicated by dashed lines. Open box, 50-UTR; grey box, coding sequence. The positions of the TaqmanVR gene expression assays used in RT-qPCR are also indicated. (B)
The average read count of SERPINF1 exons is shown in eight otosclerotic and four control stapes subjected to RNA-seq analysis, the read count of the stapes from the
proband of family B with a c.601G>A mutation is also shown separately. Data indicate a significant difference in expression between otosclerotic and control stapes of
exons 5–8 but not exons 1–4. (*P<0.05. Error bars indicate standard error of mean. A student’s two-tailed t-test was performed.) (C, D) RT-qPCR data show the average
relative expression levels of (C) upstream (exons 3–4) and (D) downstream (exons 6–7) SERPINF1 exons in stapes from: control individuals (n¼5), otosclerosis patients
(n¼75) and stapes from one individual with a SERPINF1 mutation (c.441G>C). Expression levels were calculated relative to 18s RNA endogenous control and to levels
in controls (calibrator sample). Levels of SERPINF1 are significantly reduced in the otosclerotic stapes and in c.441G>C for both assays, a greater reduction being de-
tected in downstream exons. Error bars indicate 95% confidence intervals (*P<0.05; ***P< 0.0005; ****P<0.00005 in a Student’s two-tailed t-test performed on DDCt val-
ues compared with control sample).
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38delTCG variant showed a marked difference in both the 50-UTR
and full mRNA folding predictions.
To confirm whether the 50-UTR mutations have effects on
protein production, luciferase constructs containing wild-type
and mutant 50-UTR sequences were tested in MG-63 cells
(Fig. 3A). Compared with the wild-type construct, the c.440-
40_440-38delTCG and c.441G>C alleles showed a significantly
reduced level of luciferase activity (Fig. 3B), indicating that these
variants will likely reduce the translational efficiency of the
SERPINF1-012 transcript. The c.601G>A allele also had a signifi-
cant influence on luciferase activity; however, a significant in-
crease in translational activity was observed.
Discussion
Despite its high prevalence and disease burden, the impact of
hearing impairment on quality of life is often underestimated.
Hearing loss can lead to social isolation and depression, and is
associated with cognitive decline (40–44). Otosclerosis is one of
the most common causes of hearing impairment in young
adults and has a significant detrimental effect upon patients
(45). Despite the importance of the disease, the genetic path-
ways and aetiology of otosclerosis remain poorly understood.
Using a WES approach we identified a rare SERPINF1 mutation
in a family affected by an autosomal dominant otosclerosis.
Five additional mutations were identified in six individuals
across a cohort containing 84 unrelated individuals with a fam-
ily history of otosclerosis meaning that 8.0% of familial otoscle-
rosis patients had a rare SERPINF1 mutation. Three of these
variants have not been reported in the relevant ethnic groups of
the 1000 Genomes and NHLBI exome sequencing project and
the remaining variants are extremely rare in the same studies
(see Table 2). Of the six mutations identified, three are predicted
to be deleterious to the protein function of the major SERPINF1
transcript (SERPINF1-001; Table 3). The remaining three muta-
tions are predicted to have benign effects on SERPINF1-001;
however, they lie within the 50-UTR of an alternative transcript,
SERPINF1-012. Assessing the contribution of non-coding vari-
ants to disease is limited by lack of knowledge of the effect of
such variants. Here, we utilized transcriptomic data in the form
of RNA-seq from the relevant tissue to reveal that the alterna-
tively spliced SERPINF1-012 transcript is the major transcript
found in stapes bone, indicating that it plays a role in this tis-
sue. Furthermore, both c.441G>C and c.601G>A 50-UTR vari-
ants result in reduced levels of the exons present in this
transcript in stapes bone of the affected patient, suggesting that
they alter expression of this transcript. Stapes was unavailable
from the patient with the c.440-40_440-38delTCG mutation. The
impact of these three 50-UTR variants was further assessed us-
ing in vitro luciferase assays, showing that all three SERPINF1-
012 50-UTR mutations had a significant impact on the transla-
tion of the reporter gene (see Fig. 3), highlighting the functional
importance of the identified mutations. Whether these effects
are mediated by altering transcription or translation remains to
be demonstrated but it is intriguing that two of the variants are
predicted to create binding sites for transcription factors known
to be involved in regulating bone turnover; PAX3, RBPJ and
NFYA (36–38). PAX3 and RBPJ have both been shown to play in-
hibitory roles in bone formation, whereby persistent PAX3 ex-
pression inhibits BMP-induced osteogenesis (36) and activation
of RBPJ inhibits TNF-induced osteoclastogenesis (37). In osteo-
sarcoma cells, NFYA has been shown to stimulate transcription
of bone sialoprotein, a major protein in the extracellular matrix
of bone (38). This raises the possibility that the pathological
mechanism is aberrant transcriptional regulation of SERPINF1-
012 leading to dysregulated bone regulation.
The most surprising observation in our study is that
SERPINF1-012 expression is also reduced in stapes from a het-
erogeneous cohort of 75 unrelated otosclerosis patients (Fig.
2D). This heterogeneous set of patients included both sporadic
and familial cases, which suggests that reduction of this tran-
script may be a common pathway in the pathology underlying
otosclerosis. Therefore, other genes in this pathway may also
represent good candidates for mutation in other familial
cases.
SERPINF1 encodes PEDF (pigment epithelium-derived growth
factor), a collagen-binding protein that is highly expressed in
collagen-rich tissues including bone, cornea and cartilage. PEDF
is a potent inhibitor of angiogenesis (46), and the collagen-bind-
ing property of PEDF has been elucidated to be important for its
anti-angiogenic activity (47). Interactions between angiogenic
and osteogenic pathways are known to be essential in bone for-
mation, repair and remodelling (48), highlighting PEDF as a good
biological candidate in otosclerosis. Additionally, PEDF is known
to bind to heparan sulphate, a glycosaminoglycan which regu-
lates transforming growth factor beta (TGF-b) signalling by mod-
ulating the assembly of latent TGF-b1 (49). TGF-b1 is a
polypeptide abundant in the bone matrix that is known to be a
potent stimulator of osteoblastogenesis and inhibitor of osteo-
clastogenesis, for which reason it has been repeatedly proposed
as an otosclerosis candidate gene (50–52). Various members of
this family including TGF-b1 and bone morphogenetic proteins
BMP2 and BMP4 have been associated with otosclerosis in some
candidate gene association studies but not all (22,23,52–54);
however, a precise role for this gene family in development of
Figure 3. Mutations in the 50-UTR influence translational efficiency of the
SERPINF1-012 transcript. (A) Fragments containing the wild-type or mutant 50-
UTRs of the SERPINF1-012 transcript were cloned into the pGL4.10 expression
vector and transfected into MG-63 cells. (B) For the luciferase assay wild-type
values were set to 1, to which mutant values were normalized. These results are
the average of 12 repeats in four independent experiments. The c.440-40_440-
38delTCG (3bpDel) and c.441G>C mutations show a significant reduction in
translational activity, whereas the c.601G>A mutation displays a significant in-
crease. Error bars indicate standard error of mean (*P< 0.05; **P<0.01 in a
Student’s two-tailed t-test versus control data).
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otosclerosis has not been defined. The identification of
SERPINF1 mutations in patients with familial otosclerosis in this
study and the altered stapes expression observed in the gene
that encodes PEDF provide a new link between heparan sul-
phate and modulation of TGFb signalling in otosclerosis.
Furthermore, heparan sulphate has been shown to compete
with PEDF in interactions with collagen, due to overlapping
binding sites (55), highlighting a possible functional relationship
between collagen, PEDF and heparan sulphate during angiogen-
esis. Some of the residues involved in heparan binding are ab-
sent from the shorter alternatively spliced SERPINF1-012
transcript, which could have a significant impact on its role in
angiogenesis and bone regulation in the stapes compared with
SERPINF1-001 in other bone.
Mutations in SERPINF1 are already known to underlie one
recessive form of the connective tissue disorder osteogenesis
imperfecta (OI) type VI (MIM: 613982). OI is a brittle bone dis-
order caused by mutations in COL1A1 or COL1A2 in over 90%
of cases; with mutations in many other genes, including
SERPINF1, responsible for the other 10% of cases. To date 20
unique sequence variants in SERPINF1 have been identified in
OI type VI patients (56–65). Most of the reported variants are
nonsense or frameshift mutations that are expected to cause
mRNA instability due to nonsense-mediated decay, leading
to complete loss of PEDF expression (60). The three SERPINF1
in-frame deletions or insertions identified in OI lead to reten-
tion or degradation within cellular compartments and
thereby interfere with PEDF secretion (66). Although it is ex-
pected that a loss of PEDF results in production of under-
mineralized bone, the mechanism by which this occurs is un-
known. In bone, as PEDF binds to collagen with high affinity
and is actively expressed in osteoblastic regions of active
bone formation, it is possible that PEDF plays an important
functional role in bone matrix remodelling (67). Some pa-
tients with OI experience conductive hearing loss similar to
that of otosclerosis. These similarities have previously led re-
searchers to postulate that otosclerosis and OI may have a
common aetiology (68). Therefore, given SERPINF1’s known
role in bone regulation these data suggest SERPINF1 is an ex-
cellent candidate for an otosclerosis gene. Importantly, all of
the otosclerosis patients with SERPINF1 mutations display no
OI and have not reported a disproportionate amount of bro-
ken bones. One patient reported having osteoporosis and
rheumatoid arthritis.
In contrast to OI, none of the mutations described here in
the otosclerosis cohort are nonsense or frameshift mutations,
so it is unlikely that they would lead to nonsense mediated de-
cay. The variants identified were found to have a more subtle
effect on SERPINF1 function. The three missense variants pre-
dicted to be deleterious to the protein function of SERPINF1
(c.167C>G, c.331G>A and c.392C>A) would be expected to
only cause a partial loss of PEDF function rather than the com-
plete loss of PEDF expression seen in OI patients. The c.440-
40_440-38delTCG, c.441G>C and c.601G>A variants identified
in the 50-UTR of SERPINF1-012 were shown to have a significant
impact on the translational efficiency of this transcript; there-
fore, it is possible that these variants primarily affect an alter-
natively spliced transcript which is critical for stapes
maintenance but redundant in other bone (Fig. 4). This could
explain the phenotypic differences seen between OI and oto-
sclerosis and would support the suggestion that they have a
common aetiology.
The results from this study indicate that WES is a useful tool
for investigating disease-causing variants in families exhibiting
autosomal dominant inheritance of otosclerosis. The step-wise
variant prioritization process has been effective at narrowing
down the large number of potential disease-causing variants
from an average of 89 656 variants per family to a small pool of
those that are most likely to be involved in the disease process.
Ultimately, our results demonstrate the power of an exome se-
quencing approach over linkage analysis in familial cases of a
relatively common disorder, even in the presence of variable
penetrance and heterogeneity. It also shows the value of tran-
scriptome data in the filtering and prioritization of variants,
highlighting SERPINF1 as the first disease-associated gene to be
identified in otosclerosis.
Figure 4 Proposed role of SERPINF1-012 expression in otosclerosis pathophysiology. The alternatively spliced SERPINF1-012 transcript (shown in red) is the major tran-
script found in healthy stapes bone, whereas SERPINF1-001 (shown in blue) has a lower level of expression. Reduced expression of SERPINF1-012 expression by mutation
in familial cases or by other means in sporadic otosclerosis leads to localized stapes bone dysregulation and otosclerosis. Loss of SERPINF1-001 expression due to
frameshift and nonsense mutations in osteogenesis imperfecta causes systemic bone dysregulation.
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Materials and methods
Patient recruitment
Individuals with a confirmed diagnosis of otosclerosis were re-
cruited from the Royal National Throat Nose and Ear Hospital,
London, UK and The Princess Margaret Hospital in Windsor.
The study was approved by the London Bloomsbury NRES
Ethics committee (11/LO/0489) and patients were recruited by
informed consent. From this cohort, a sub-cohort of individuals
with evidence of familial otosclerosis was identified based on
patient questionnaire data of family history (defined as two or
more relatives with otosclerosis). Blood or saliva samples
(OrageneVR Saliva Kit, DNA Genotek) were obtained for genomic
DNA isolation by standard methods. For those patients under-
going stapedotomy surgery to remove the stapes superstruc-
ture, the tissue was retained for gene expression studies.
Control stapes were obtained from individuals where the stapes
was removed as part of surgery for a number of other indicators
including head trauma, glomus tumour and during total
petrosectomy.
WES and filtering
WES was performed at the Wellcome Trust Sanger Institute on
genomic DNA isolated from each of the 10 individuals selected
from four families with familial otosclerosis. The sequencing
data have been deposited at the European Genome-phenome
Archive (EGA; EGAS00001000156). After target enrichment using
Agilent SureSelect Human All Exon V3 kit the whole-exome
DNA library from each participant was sequenced using
Illumina HiSeq 2000 with 100 bp paired-end reads and mapped
to the reference human genome (GRCh37_hs37d5) based on the
sequence alignment. Both single-nucleotide variants and indels
were identified using SAMtools (69), GATK (70) and Dindel (71).
A mean of 16.5 Gb of sequence was generated per sample with
an average of 96.16% of the bases mapping to the reference ge-
nome at a coverage of at least 10. The mean depth of coverage
was 178.5. Of all the variants mapped, 93.7% met a quality
score threshold of 30. The filtering strategy applied to the data
is described in Table 1 and in the main text.
Segregation analysis and mutation detection
All variants prioritized for follow-up were confirmed by Sanger
sequencing in the relevant family. Genotyping for segregation
analysis was performed by Sanger sequencing. In segregation
analysis, variants were excluded if they were present in more
than one unaffected individual above the age of onset of oto-
sclerosis in that family. Variants were also excluded if they
were not present in all individuals with otosclerosis. Sanger se-
quencing was used for genotyping in the unrelated familial oto-
sclerosis cohort. PCR primers used to amplify the SERPINF1
exons are shown in Supplementary Material, Table S1.
RNA-seq and RT-qPCR analysis
Human stapes were preserved in AllProtectTM Solution (Qiagen)
and stored at –80 C. Stapes were homogenized in QIAzol Lysis
reagent and RNA purified using the RNeasy lipid tissue mini kit
(Qiagen) according to the manufacturer’s protocol, including an
on column DNase digest. RNA was reverse transcribed into
cDNA by Clontech SMARTerTM kit for RNA-seq and by
Omniscript Reverse Transcriptase Kit for RT-qPCR. The integrity
of the cDNA for RNA-seq was confirmed on an Agilent
Bioanalyzer 2100 before sending to Otogenetics Corp (Norcross,
GA, USA) where cDNA fragmentation was performed on the
samples and cDNA libraries constructed before 100 bp paired-
end RNA sequencing using Illumina HiSeq 2000 was carried out.
Paired-end 100 nt reads were aligned to human genomic assem-
bly hg19 and visualized on the DNAnexus platform (Mountain
View, CA, USA). TaqmanVR gene expression assays were per-
formed on human otosclerotic and control cDNA samples. RT-
qPCR was conducted using an SDS7500 real time PCR machine
(Applied Biosystems) with primer/probe pairs obtained from
Applied Biosystems. SERPINF1 assays spanning exons 3–4
(Assay ID: Hs011006934_m1) and exons 6–7 (Assay ID:
Hs011006937_m1) were performed with eukaryotic 18s RNA as
an endogenous control. Relative quantification of SERPINF1 was
calculated relative to a calibrator sample (control stapes) using
the DDCt method.
In silico analysis of 50-UTR variants
MatInspector (35), a transcription factor prediction tool, was
used to identify potential transcription factor binding sites in
the region where the variants in the 50-UTR of the SERPINF1-012
transcript were found. The matrix score calculates a match be-
tween the sequence and the matrix, ranging from 0 to 1, with 1
indicating an exact match. Putative RNA folding structures were
predicted using Mfold (39) with standard settings.
Cloning of SERPINF1-012 50-UTR variants
The Gibson assembly cloning method (72) was used to insert
the DNA fragments of three SERPINF1-012 50-UTR variants into
pGL4.10 vector separately, as well as a wild-type control. Gibson
assembly primers for SERPINF1-012 fragments were synthesized
(Supplementary Material, Table S2), and inserts were prepared
by PCR amplification using the Q5 High-Fidelity PCR kit (New
England Biolabs) and gDNA as a template. PCR products were
used in DNA assembly reaction with PCR-linearized pGL4.10
vector using Gibson Assembly Cloning kit (New England
Biolabs). Each assembly reaction contained approximately
150 ng of insert and 50 ng of the expression vector and incu-
bated at 50 C for 1 h following the manufacturer’s protocol.
After the assembly reaction, the reaction mix was transformed
into NEB 5-alpha competent E. coli strain (New England Biolabs).
After an overnight growth at 37 C, the pGL4.10 plasmids con-
taining respective inserts were extracted using a QIAprep Spin
Miniprep Kit (Qiagen) and constructs were verified by Sanger
sequencing.
Transfection and luciferase activity assay
To measure the translational activity of the 50-UTR variants of
SERPINF1-012, dual-luciferase reporter assays were conducted
in MG-63 cells. The human osteosarcoma MG-63 cell line was
obtained from Dr Vehid Salih at the Eastman Dental Hospital,
University College London. MG-63 cells were cultured in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen) and
were maintained at 37 C in a 5% CO2 incubator. Medium was
supplemented with glutamax, 10% foetal bovine serum and 1%
penicillin/streptomycin. MG-63 cells (1  105) were seeded on 6-
well plates and transfected 24 h later using the calcium phos-
phate method (73). A total of 270 ng plasmid DNA (250 ng of
pGL4.10 constructs and 20 ng phRL-null) was used for each
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transfection. After incubation for 16 h, cells were exposed to
glycerol shock condition with 2 ml of 15% glycerol containing
DMEM for 2 min 30 s. Subsequently, the mixture was aspirated
and replaced with fresh DMEM supplemented with glutamax,
10% foetal bovine serum and 1% penicillin/streptomycin. Cells
were harvested 48 h after transfection, and luciferase activities
were measured with the Dual-LuciferaseVR Reporter Assay
System (Promega) and a single-tube luminometer (Turner
BioSystems). Luciferase activities shown in figures are the mean
of 12 transfections in four independent experiments.
Web resources
The URLs for data presented herein were last accessed on
February 23, 2016 and are as follows:
1000 Genomes, http://www.1000genomes.org/
Ensembl, http://www.ensembl.org/
European Genome-phenome Archive (EGA), https://www.
ebi.ac.uk/ega/
MatInspector, https://www.genomatix.de/matinspector
Mfold, http://unafold.rna.albany.edu/?q¼mfold
MutationTaster, http://mutationtaster.org/
NHLBI ESP Exome Variant Server, http://evs.gs.washington.
edu/EVS/
OMIM, http://www.omim.org/
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/
SIFT, http://sift.jcvi.org/
Supplementary material
Supplementary Material is available at HMG online.
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